Treatment optimisation trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparison of 6 cycles of escalated BEACOPP with 6 cycles of BrECADD.
Phase 3
Active, not recruiting
- Conditions
- Advanced stage Hodgkin lymphomaCancer - Hodgkin's
- Registration Number
- ACTRN12617000087358
- Lead Sponsor
- niversity of Cologne
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- All
- Target Recruitment
- 1585
Inclusion Criteria
Histologically proven classical Hodgkin lymphoma;
- First diagnosis, no previous treatment
- Stage IIB with large mediastinal mass and/or extranodal lesions, stage III or IV.
- Main cohort: 18 to 60 years of age;
- Older cohort: 61 - 75 years of age.
Exclusion Criteria
- Composite lymphoma or nodular lymphocyte predominant Hodgkin lymphoma;
- Previous malignancy (exceptions: basalioma, carcinoma in situ of the cervic uteri, completely resected melanoma TNMpT1);
- Prior chemotherapy or radiotherapy;
- Concurrent disease which precludes protocol treatment;
- Pregnancy, lactation;
- Non-compliance.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method